Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide

Clinical Medicine Insights: Oncology - New Zealand
doi 10.4137/cmo.s11670
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

SAGE Publications

Related search

Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-Resistant Prostate Cancer After Chemotherapy

Klinicka Onkologie
Oncology
2016English

Initial Experience of the Enzalutamide Treatment for Castration-Resistant Prostate Cancer

Japanese Journal of Urology
Urology
2016English

Budget Impact Analysis of Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer From a u.s. Payer Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Plasma Levels of Enzalutamide and Its Main Metabolites in a Metastatic Castration-Resistant Prostate Cancer Patient Undergoing Hemodialysis

Clinical Genitourinary Cancer
OncologyUrology
2019English

Patient Reported Outcomes in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2018English

Patient Reported Outcomes in Metastatic Castration-Resistant Prostate Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Pcn346 - Disease Specific Cost Analysis of the Nonmetastatic Castration-Resistant Prostate Cancer and Metastatic Castration-Resistant Prostate Cancer Health States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Mp52-01 Combination of Indomethacin and Enzalutamide to Treat Castration-Resistant Prostate Cancer

Journal of Urology
Urology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy